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Background: Considerable work has been carried out to understand the biology of tachyzoites and bradyzoites
of Toxoplasma gondii in large part due to in vitro culture methods for these stages. However, culturing methods
for stages that normally develop in the gut of the definitive felid host, including the merozoite and sexual stages,
have not been developed hindering the ability to study a large portion of the parasite’s life cycle. Here, we begin
to unravel the molecular aspects of enteric stages by providing new data on merozoite stage gene expression.
Results: To profile gene expression differences in enteric stages we harvested merozoites from the intestine of
infected cats and hybridized mRNA to the Affymetrix Toxoplasma GeneChip. We analyzed the merozoite data in
context of the life cycle by comparing it to previously published data for the oocyst, tachyzoite, and bradyzoite
stages. Principal component analysis highlighted the unique profile of merozoites, placing them approximately
half-way on a continuum between the tachyzoite/bradyzoite and oocyst samples. Prior studies have shown that
antibodies to surface antigen one (SAG1) and many dense granule proteins do not label merozoites: our microarray
data confirms that these genes were not expressed at this stage. Also, the expression for many rhoptry and
microneme proteins was drastically reduced while the expression for many surface antigens was increased at the
merozoite stage. Gene Ontology and KEGG analysis revealed that genes involved in transcription/translation and
many metabolic pathways were upregulated at the merozoite stage, highlighting unique growth requirements
of this stage. To functionally test these predictions, we demonstrated that an upstream promoter region of a
merozoite specific gene was sufficient to control expression in merozoites in vivo.
Conclusions: Merozoites are the first developmental stage in the coccidian cycle that takes place within the gut of
the definitive host. The data presented here describe the global gene expression profile of the merozoite stage and
the creation of transgenic parasite strains that show stage-specific expression of reporter genes in the cat intestine.
These data and reagents will be useful in unlocking how the parasite senses and responds to the felid gut
environment to initiate enteric development.
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Intracellular parasites represent a significant portion of
human disease burden throughout the world. The api-
complexan parasite Toxoplasma gondii is one of the
most successful intracellular parasites and it is estimated
up to a third of the human population has been infected
[1]. This high infection rate results in approximately 1.5
million new infections in the U.S. per year. Fortunately,
most infections do not result in debilitating symptoms
as individuals with healthy immune systems are able to
control the growth of the parasite, yet they are generally
not able to eliminate chronic infection. Toxoplasmosis
has been an indicator disease for patients suffering from
complications of AIDS since the advent of the HIV viral
epidemic [2]. Unborn babies can become infected in
mothers who convert during pregnancy, resulting in 400–
4,000 new congenital toxoplasma infections in the U.S.
per year [3]. Also, the parasite can thrive in immune
privileged areas of the eye, resulting in approximately
5,000 symptomatic ocular toxoplasmosis cases in the
U.S. every year [4]. Major routes of human infection
are via either the ingestion of undercooked infected
meat or the accidental ingestion of oocysts shed into
the environment, for example, by gardening or cleaning
cat litter. Recent estimates by the CDC indicate that of
known etiological agents, toxoplasmosis is the fourth
leading cause of hospitalization and the second lead-
ing cause of death by foodborne illness in the U.S today
[5]. The ability of Toxoplasma to infect such a large
number of individuals, approximately 30 million in the
U.S., results in meaningful disease burden in those indi-
viduals where the parasite circumvents normal modes
of control [6].
There are two aspects of the Toxoplasma life cycle that
allow it to be so prevalent, the ability to infect a vast num-
ber of intermediate hosts and the ability to produce mil-
lions of environmentally resistant oocysts through a single
infection of a cat, the definitive host [7]. Toxoplasma
gondii has been found to infect virtually every warm
blooded animal that has been assessed [8]. Because of
this, many animals used for food consumption have
dormant bradyzoite cysts in their tissues, and if not prop-
erly cooked, these parasites can be passed to the consumer
leading to infection. This points out a unique feature of
the T. gondii life cycle, as permissive infection of inter-
mediate hosts following ingestion of tissue cysts [9] is nor-
mally only infective for the definitive host in related
apicomplexan parasites [10]. Upon infection, slow growing
bradyzoites differentiate into rapidly growing tachyzoites
that continue to divide and rupture infected cells caus-
ing cellular damage. Once the immune system is triggered,
parasite growth is controlled, and the parasite differentiates
back into the dormant bradyzoite cyst effectively hiding
from the immune system, often in immune privileged areassuch as the brain. This bradyzoite-tachyzoite-bradyzoite
progression can result in repeated rounds of infection in
multiple intermediate hosts, without the need for sexual
transmission. In order to complete the life cycle and dif-
ferentiate into sexual stages, the parasite must pass
through the gut of a felid. Although, fortunately, cat pre-
dation of humans is extremely rare, cats can be exposed
to the parasite by ingesting other infected intermedi-
ate hosts, such as mice. Once bradyzoites pass into
the intestine of a cat they can differentiate through
the coccidian stages of development, or enteric stages,
progressing from asexual merozoite forms into sexual
stage micro- and macrogametocytes that eventually fuse
to form oocysts which are shed into the environment
where they mature into sporulated oocysts. Sporulated
oocysts can then be ingested by intermediate hosts,
where infectious sporozoites liberated from oocysts
differentiate into tachyzoites completing the life cycle
(Figure 1A) [7,11].
Much work has been carried out to understand the
biology of the asexual stages, tachyzoites and brady-
zoites, which occur in the intermediate host. One reason
for this is the relative ease in culturing these stages in
the laboratory, both in tissue culture and the mouse
model. Tachyzoites grow well in various cell lines, such
as human foreskin fibroblasts (HFFs), and bradyzoites
can be induced in vitro [12,13] via cellular stresses
[14,15] or in vivo. These culturing methods have allowed
researchers to develop an extensive molecular toolbox
for Toxoplasma, resulting in an increased understanding
of its biology including host cell invasion and egress
[16], how the parasite modulates the intracellular envir-
onment [17], and the identification and characterization
of virulence factors that allow the parasite to evade host
innate immune defenses [18]. Culturing methods for
stages beyond the bradyzoite, the merozoite and sexual
stages, have not been developed, hindering the ability to
study a large portion of the parasites life cycle and
restricting such work to a few laboratories with the re-
sources to house cats.
There are several reports describing various aspects of
the enteric stages of T. gondii within felid intestinal cells
[19-22]. These studies used electron microscopy to ob-
serve ultrastructural features or performed immunohis-
tochemistry (IHC) to determine the labeling of parasites
with various antibodies, useful in characterizing the ex-
pression of a limited number of proteins in enteric
stages. Another report demonstrated the feasibility of
isolating merozoite stage parasites from the intestinal
mucosa of infected cat intestine [23] and showed these
parasites illicit unique antigenic responses [24]. Based
on this report, we undertook isolation of merozoites for
genome wide expression profiling study in order to iden-
tify merozoite-specific genes.
Figure 1 Life cycle of Toxoplasma gondii, and the harvest and hybridization of merozoite mRNA. (A) Life cycle of Toxoplasma gondii [58].
Green circle highlights stages for which microarray expression data exists [27]. Red circle highlights merozoite stage harvested for this study.
(B) We obtained intestines from three cats (c48, c50, c52) that had been orally infected 5–6 days previously with the type II parasite TgNmBr1strain in
order to isolate merozoite stage parasites. To determine that the purified forms were indeed Toxoplasma, a portion of sample c52 was labeled with
mouse α-Me49 (Alexa Fluor 488, yellow). DAPI stained nuclei (blue). (C) mRNAs for two merozoite c52 (Mc52) samples and one for each of the c48
(Mc48) and c50 (Mc50) samples were labeled using the Ambion MessageAmp kit and hybridized to Affymetrix Toxoplasma GeneChips. In order to
control for possible strain specific expression we also hybridized two TgNmBr1 tachyzoite mRNA samples (TNm). Data were analyzed in
combination with the recently published dataset covering oocyst (Day 0 (OD0), 4 (OD4), 10 (OD10)) to tachyzoite (TD2) to bradyzoite
(Day 4 (BD4), 8 (BD8), 21 (BD21)) development in the type II M4 strain [27]. Boxplots of the RMA normalized data show similar distributions and
median values across the samples.
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Isolation of merozoite stage parasites and mRNA
hybridization
To provide insight into gene expression of the enteric
stage, we harvested intestines of three cats (cat numbers:c48, c50, and c52) infected with the type II parasite,
TgNmBr1 [25]. The harvesting process resulted in the
removal of the majority of host cells and debris, leaving
crescent shaped merozoite parasites. To determine that
the purified parasites were indeed T. gondii, a portion of
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munized with type II Me49 parasites (Figure 1B). Indeed,
the crescent shaped purified parasites were labeled with
the Toxoplasma specific antibody. Purified parasites from
all three felid intestines were processed for mRNA isola-
tion and hybridized to the Affymetrix Toxoplasma Gene-
Chip [26] (array sample names: Mc48, Mc50, and Mc52).
In order to place the newly acquired merozoite gene ex-
pression in context of the life cycle, the data were analyzed
in combination with a recently published dataset by Fritz
HM et al. 2012 [27] covering day 0, 4, 10 oocyst (array
sample names: OD0, OD4, OD10), day 2 tachyzoite (TD2),
and day 4, 8, 21 bradyzoite (BD4, BD8, BD21) development
(Figure 1C). Although the parasites used in the present
study (TgNmBr1 strain) and the Fritz HM et al. study [27]
(M4 strain) are both clonal type II strains, they are of dif-
ferent origins; the former is from a guinea fowl from Brazil,
and the latter is from a sheep in United Kingdom. To
control for any strain specific differences in identifying
merozoite specific genes, we also hybridized mRNA from
TgNmBr1 tachyzoites (TNm). Plotting of RMA normal-
ized values for all the samples used in the analysis demon-
strated that the medians of the distributions converge and
that the ranges of extreme values across all samples were
similar, lending weight that the samples from the current
study and the Fritz HM et al. [27] study are comparable
(Figure 1C).
Life cycle gene expression analysis
In order to verify that the purified parasites were enteric
stage merozoites, and not morphologically similar tachy-
zoites, we used as a control a gene list for which the expres-
sion status at the merozoite stage had been determined
using immunohistochemistry (IHC) [20]. Comparison
of the IHC data on protein expression showed excellent
agreement with the merozoite gene expression data
(Figure 2A). For example, Ferguson DJ [20] reported
that antibodies to surface antigen 1 (SAG1) and many
dense granule proteins (GRAs) did not label merozo-
ites, and the microarray data from all three merozoite
samples (Mc48, Mc50, and Mc52) confirmed that these
genes were not expressed at this stage. Likewise, the ex-
pression pattern was consistent in both experiments for
genes that were expressed in merozoites, such as enolase
2 and LDH1, which were not expressed in bradyzoites but
were expressed in the tachyzoite and merozoite stages
(Figure 2A). The agreement between these datasets sup-
port the conclusion that the parasites harvested from the
infected felid intestines are indeed merozoites.
To determine the major trends across the samples
we conducted principal component analysis (PCA) that
highlighted the uniqueness of the merozoite samples
(Figure 2B), clustering them approximately half-way on a
continuum between the tachyzoite/bradyzoite and oocystsamples. The distinct grouping of the merozoite samples
was not the result of strain specific differences as the
tachyzoite TgNmBr1 strain sample (TNm), the same strain
used to generate the merozoite parasites, grouped with
the tachyzoite M4 strain Day 2 sample (TD2) Interest-
ingly, the PCA analysis revealed that compared to the
merozoite and oocyst stages, the tachyzoite and bradyzoite
stages were quite similar and they all group together.
Although studies have shown there are gene expression
differences between these two stages [28-30], the PCA
of global expression profiles indicates that bradyzoites
resemble dormant tachyzoites when taken in context
of the whole life cycle. Lastly, the circular progression
of samples, from the OD0 to OD4/OD10 cluster, to the
tachyzoite/bradyzoite cluster, and finally to the merozoite
cluster, follows the progression of the life cycle (Figures 1A
and 2B).
We identified life cycle regulated genes by performing
an analysis of variance test (ANOVA p-value cutoff .05)
on genes with expression above background levels in at
least one sample. This analysis resulted in the identi-
fication of 5,969 genes, a large proportion (73.4%) of
the genes in the Toxoplasma genome. There were 1,571
non-expressed genes (19.3%) for which expression was
at or below background in all samples, and 591 non-
regulated genes (7.3%) that were not significantly dif-
ferentially expressed between the samples. Although
the life cycle regulated gene set (5,969) captures most
of the T.gondii genome, a fifth of the genes represented
on the array did not have detectable expression. Some of
these non-expressed genes may represent stage specific
genes for stages which we do not have expression data,
such as the micro- and macrogametes.
The regulated genes (5,969) were clustered into a heat-
map revealing that the merozoite samples have a unique
gene expression profile with hundreds of genes increased
or decreased as compared to the other life cycle stages
(Figure 3A). This pattern was consistent for all three
merozoite samples. Many different expression patterns
emerge from the heatmap (Figure 3A), but one major
theme is the large number of genes that were differen-
tially regulated at the merozoite and oocyst stages as
compared to the tachyzoite and bradyzoite stages. When
a 2.5 fold expression cutoff was applied on the Mc52
sample, 1,918 of the regulated genes (32.1%) were specif-
ically regulated at the merozoite stage, with 1,249 being
upregulated and 669 genes downregulated at this stage.
To identify biological processes that may be life cycle
regulated, we performed standard Fisher’s exact tests on
overlapping genes between the regulated gene list (5969)
and a comprehensive set of lists based on Gene Ontology
(GO). The two most significant GO lists were cell growth
& maintenance (p-value 1.92e-251) and metabolism
(p-value 5.7e-153). More specifically, within these
Figure 2 Merozoite gene expression supports published data and forms a distinct grouping when compared with other life cycle
stages. (A) Heat map of expression (left, this study) and binary indication of labeling by IHC (right) for genes that were assessed for merozoite
stage expression previously [20]. There was excellent agreement when the two studies are compared, where, for example, gene products that
did not label by IHC at the merozoite stage (−) were not expressed as indicated by the microarray data (blue). (B) Principal component analysis
(PCA) highlighted the unique profile of the merozoite samples placing them approximately half-way on a continuum between the tachyzoite/
bradyzoite and oocyst samples. The first two components described a combined 75% of the variance across the samples.
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interest; Translation (p-value 2.39e-52), Transcription
(p-value 2.9e-20), and Glycolysis & TCA (p-value 5.75e-5)
(Figure 3B). The heat maps show that many genes within
these GO categories are uniquely upregulated at the
merozoite stage (Figure 3B). Especially striking were the
large number of genes upregulated in the Glycolysis/TCA
and Purine/Pyrimidine metabolic pathways. To further
extend the metabolic analysis we mapped the expres-
sion of all the regulated genes for which there are KEGGannotations (KEGG genome T01093) to the KEGG meta-
bolic pathways map (tgo01100), creating maps for each life
cycle stage (see Additional file 1). Two major themes were
revealed in these metabolic maps. First, many pathways
started from a downregulated state (blue) at the OD0
sample, progressively increased in expression through
OD4 and OD10, exhibited steady state expression in the
tachyzoite and bradyzoite samples (yellow), and, finally,
pathways throughout the metabolic map were upregulated
at the merozoite stage (red). Secondly, the expression of
Figure 3 Clustering of significantly regulated life cycle gene groups. (A) Heatmap of life cycle regulated genes. A total of 5,969 genes were
found to have significant expression differences (ANOVA .05). (B) Heatmap of cell growth related genes. Many genes with growth and/or
metabolism related Gene Ontology were upregulated at the merozoite stage. (C) Heatmap of Apicomplexa specific genes. The ROP, GRA and
MIC gene families were downregulated as a class and many SRS genes were upregualted upon entering the enteric stages.
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pathways oscillates throughout development (two repeat-
ing sets of vertical pathways at left of center in Additional
file 1: FAB left set, FAD right set). FAB was downregulated
in the OD0, OD4 and OD10 samples, steady state in
tachyzoite and bradyzoite, and upregulated in the merozo-
ite. In an opposite manner to FAB, FAD was largelydownregulated in the invasive stages, the tachyzoite and
merozoite, and upregulated in the encysted stages, the oo-
cysts and bradyzoite. The regulation of the FAD pathway
through life cycle development may provide the encysted
stages a poised state to utilize fatty acid stores that are
present, for example, in the oocyst [31]. Overall, the GO
and KEGG analysis demonstrated that the merozoite has
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metabolic related genes, indicating unique growth require-
ments of this stage.
We also looked at the expression of parasite-specific
gene families in the merozoite stage. As seen in Figure 2A,
many of the annotated GRA genes (50%) are not expressed
at the merozoite stage (Figure 3C). Genes in two other
parasite specific gene families, the rhoptry (ROP) (61%)
and microneme (MIC) (60%), similarly lacked expression
in the merozoite stage. For example, none of the annotated
rhoptry neck (RON) or apical membrane (AMA) genes,
important for parasite invasion in intermediate stages, were
expressed at the merozoite stage. One RON paralog,
RON4L1 [27], had slight expression in the merozoite, but
the expression was downregualted as compared to the
tachyzoite/bradyzoite stages. Likewise, genes that have
been shown to be important for host immune evasion,
such as ROP18, ROP5, ROP16, GRA15, and GRA24
[18,32], were not expressed. Although essentially half of
the genes in these gene families were not expressed as
merozoites, others had low constitutive expression, and a
few were upregulated. Those that exhibited upregulated
expression include: GRA family (DG32 antigen, DG32
protein, GRA12 and NTPase I), ROP family (ROP21,
ROP32, ROP33, ROP36, TGME49_281790 (kinase), and
TGME49_249470 (rhoptry kinase)) and MIC family
(TGMe49_200270 (PAN/Apple domain),TGME49_275800
(SRP72), TGME49_286150 (PAN/Apple domain), and
TGME49_254430 (microneme)), but even most of these
were low abundance expressed genes. See Additional file 2
for specific genes and expression values. The downregu-
lated expression state upon entering the enteric stages for
many members of these gene families is unexpected as
many have been shown to play a role in host-parasite in-
teractions in intermediate hosts, for example invasion [33]
or host immune modulation/resistance [18], and suggests
they are not needed during enteric development. Converse
to the GRA, ROP, and MIC families, many members of
the parasite surface antigen gene family (SRS) were upreg-
ulated (44.8%) upon differentiating into the first of
the enteric stages as a merozoite (Figure 3C). Although
developmentally regulated expression of various SRS
genes has been shown for other stages, in comparison,
quite a large number were upregulated at the merozoite
stage. Members of the SRS gene family are involved in
parasite adhesion, invasion, and virulence, possible roles
they may have in allowing the parasite to develop effect-
ively in the cat intestine [34].
Timing and control of life cycle gene expression
Determining peak and valley points of expression for
gene profiles that span continuous data sets has been
useful in gaining insight into parasite biology [35,36]. By
generating spline curves from expression values for allregulated genes (5,969) we were able to determine the
points of maximum and minimum expression for each
gene. As an example, we have graphed the curves for the
SporoSAG and GRA1 genes (Figure 4A). The points of
maximum expression for GRA1 and SporoSAG were
both between the sporulated oocyst OD4 to OD10 sam-
ples, and GRA1 had a deep valley of minimum expres-
sion between the merozoite and unsporulated oocyst,
which correspond to the known roles for these genes
[20,37]. We ordered the maximum and minimum values
for all regulated genes according to the life cycle and
displayed the distribution as a histogram (Figure 4B).
There was a large shift in the number of genes at peak
expression at the merozoite stage, Mc52, corresponding
to the stage where the largest number of genes reached
maximum expression. There were also a large number
of genes that peaked throughout the oocyst stages, OD0
and OD4, while fewer genes peaked at OD10, due to its
similarity with OD4 (Figure 3A). By far, the tachyzoite
and bradyzoite stages had the fewest number of genes
peaking at those stages. A slightly different distribution
emerged when genes were ordered by minimum of ex-
pression (Figure 4B). Many genes had minimal expres-
sion throughout the enteric stages, but there were also a
large number of genes with minimum of expression be-
tween the tachyzoite and bradyzoite stages.
By calculating the maximum and minimum values of
the first derivate (f ’(x)) of the spline curve, one can de-
termine the inflection points in the graph which corres-
pond to the points of maximum rate of synthesis and
degradation. For example, GRA1 (Figure 4A) had an up-
wardly trending inflection point just after the OD0 sam-
ple corresponding to the maximum rate of synthesis just
before the peak of expression between OD4 and OD10,
and a downward trending inflection point between the
BD8 and Mc52 samples indicating the maximum rate of
degradation just before the gene is no longer expressed in
the merozoite. There was a wave of synthesis through-
out the life cycle starting with entry into the merozoite
stage, Mc52, steadily tapering through the oocyst stages
(Figure 4C). This progression largely mirrored the max-
imum expression distribution where maximum rates of
synthesis (Figure 4C) precede maximum points of expres-
sion (Figure 4B) by half a stage. The distribution seen for
maximum rate of synthesis was shifted one stage down
the life cycle when genes were ordered by maximum rate
of degradation (Figure 4C), reflecting the peak of expres-
sion that occurred between synthesis and degradation.
Lastly, we determined the time, or number of stages, to
maximum or minimum expression by subtracting the
maximum or minimum expression value (Figure 4B) for
each regulated gene from the corresponding rate value
(Figure 4C). For the upregulation of gene expression, most
genes reached peak expression very rapidly, within one
Figure 4 Timing of life cycle gene expression. (A) Example spline and f ’(x) curves for two genes, SporoSAG and GRA1. The maximum and
minimum expression values were determined from the spline curve (arrows black curve). The maximum rate of synthesis and degradation were
determined from the f ’(x) of the spline curve (arrows red curve). (B) Number of genes with maximum or minimum expression across the life
cycle calculated from spline curves for all 5,969 life cycle regulated genes. (C) Maximum synthesis and degradation rates across the life cycle
calculated from f ’(x) of spline curves for all 5,969 life cycle regulated genes. (D) For each of the 5,969 regulated genes the expression value
(B) was subtracted from the respective synthesis value (C) to determine time to maximum or minimum expression. Histograms displayed at half
stage intervals for B-D.
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the rapid synthesis of a gene the expression peaks quickly
in relation to the life cycle. This was also a result of the
stage-specific expression for many genes. When genes
were downregulated, many genes reached their minimum
of expression rapidly, but there was also a group of genes
that had a delayed minimum after the greatest rate of
degradation, approximately four stages later (Figure 4D).
This delayed grouping indicates that the minimum of ex-
pression for a large number of genes was just before the
upregulation of that gene, as there are only 6 stages repre-
sented in this analysis.
It has been demonstrated that promoter elements up-
stream of coding genes are critical for control of gene
expression in Toxoplasma, for both constitutive and de-
velopmentally regulated genes, and that minimal cis ele-
ments provide regulatory specificity [28,38-40]. Many of
the life cycle regulated genes had dramatic periodicity of
expression (Figure 3A and Figure 4), suggesting that co-
regulated genes may share common regulatory elements.
We ordered genes by maximum or minimum expression
(Figure 4B) and examined the sequence 2,000 bp up-
stream of the CDS start to search for common regula-
tory elements using FIRE [41] (Figure 5). When genes
were ordered by maximum expression (Figure 5A), 13
conserved motifs were found in promoter regions of regu-
lated genes (no motifs were found across 100 permutations
with the maximum expression data randomly ordered).
The TGCATG motif that was over represented in genes
that span the merozoite stage is a TRP2 cis element [42]
and was also found to be a major motif in a previous cell
cycle expression study [35], where TGCATG was overrep-
resented at the G1 phase of the cell cycle when genes were
ordered by maximum expression (Figure 5A arrow to
inset). Also, the GCTAGC motif overrepresented at the
OD4 stage was found in the cell cycle study, and a recent
report described an AP2 transcription factor, TgAP2-
XI-5, that binds the corresponding GCTAGC motif
[43]. TgAP2-XI-5 regulates hundreds of genes, includ-
ing ROP18, which like many of the rhoptries, increased
expression in the life cycle at OD4 from a non-expressed
state at OD0 (Figure 3C). Lastly, the ACCA(A/C/T)TG
motif, similar to the BAG1 cis element CCAGTA [28],
was overrepresented at the BD8 stage, a cluster which
contains the BAG1 gene. Ordering genes by the minimum
of expression (Figure 5B) found many motifs, 38, overrep-
resented at points that together span the whole life cycle
(no motifs were found across 100 permutations with the
minimum expression data randomly ordered). The
TGCATGC and GCTAGC motifs were found in the mini-
mum expression ordered data, along with many other
motifs that represent possible cis elements. This pat-
tern may reflect a role for repressor mechanisms con-
stituting a major portion of gene expression controlin the Toxoplasma life cycle. The FIRE analysis for the life
cycle regulated genes (Figure 5) identified overrepresented
motifs of known function (i.e., TGCATG, GCTAGC, and
ACCA(A/C/T)TG) indicating that newly identified motifs
may be functional cis elements. Additionally, motifs were
only identified when data were ordered in a biologically
relevant manner.
Promoter control of merozoite specific expression
Given that promoters have been shown to control devel-
opmental gene expression in the intermediate tachyzoite
and bradyzoite stages and that a large number of motifs
were found associated with the life cycle expression data
(Figure 5), we were interested to test if promoters were
sufficient to control gene expression at the merozoite
stage. As part of the experimental design we also sought
to drive the expression of a drug resistance gene only at
the merozoite stage. A list of 362 merozoite-specific
genes was identified by restricting the life cycle regulated
genes (5,969) to those that were not expressed in tachy-
zoite or bradyzoite stages but were upregulated in the
merozoite (Figure 6A). The expression of many of these
genes at the merozoite stage was quite high, some being
regulated > 100 fold as compared to bradyzoites. For
example, two of the SRSs, SRS22B and SRS22H, were
among the highest expressed genes in this set, and
TGME49_201180, annotated as a megakaryocyte stimu-
lating factor (MSF), was the highest expressed annotated
gene across all merozoite samples excluding the SRS
genes. These three genes were chosen as candidates to
use in cloning promoter regions into a Gateway plasmid
construct containing the drug resistance DHFR gene
tagged with a Ty epitope (DHFR-Ty). We also cloned the
GRA1 promoter (pGRA1) in front of the DHFR-Ty for
use as a control, as GRA1 is expressed in tachyzoites
and bradyzoites and not in merozoites. All four con-
structs were individually electroporated in the Me49-
Fudr parasites, as this is a type II parasite and has been
used successfully in various genetic crosses, and after se-
lection and cloning we were able to obtain transgenic
parasites containing the pGRA1, pMSF and pSRS22B
promoter constructs. The clones were screened by PCR
for integration of the plasmid using primers that span
the promoter of interest and the DHFR portion of the
construct (Figure 7A & B). The effectiveness of gene
expression control by these promoters and of the drug
resistance DHFR gene was tested by plaque assay
(Figure 7C). All three promoter strains grew equally
as tachyzoites, creating plaques after 9 days of growth
in HFF monolayers cultured with regular media lack-
ing pyrimethamine (Figure 7C top). Only the pGRA1
expressing strain grew to create plaques after 9 days in
media containing the drug (Figure 7C bottom). The pres-
ence of plaques for the pGRA1 expressing strain grown
Figure 5 Motif discovery in promoter regions of life cycle regulated genes. (A) Life cycle regulated genes (5,969) were ordered by point of
maximum expression and the FIRE software package was used to find motifs over- and under-represented in sequence 2,000 bp 5’ of the CDS
start. Motifs over-represented at a particular point in the life cycle (yellow), those under-represented (blue). (B) Life cycle regulated genes were
ordered by point of minimum expression and run in FIRE as in (A). The TGCATGC motif found in both (A) and (B) was also a major motif found
in the Toxoplasma cell cycle expression data set [35] where, for example, it was over-represented at G1 for genes with maximum expression at
that phase (inset). No significant motifs were found across 100 FIRE runs when data in (A) or (B) were randomly ordered.
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confers drug resistance, and the absence of growth for ei-
ther pMSF or pSRS22B expressing strains shows they lack
DHFR-Ty expression and remain drug sensitive. Parasites
expressing the pMSF and pSRS22B reporters were grown
for up to 18 days in pyrimethamine and no growth wasobserved by plaque assay or when the monolayers were
screened under the microscope (data not shown). We also
conducted immunofluorescence assays (IFA) on the three
strains to test for the expression of DHFR-Ty at both the
tachyzoite and bradyzoite stages. As expected, only the
pGRA1 expressing strain had detectable Ty labeling at
Figure 6 Promoter control of merozoite specific gene
expression. (A) Genes upregulated specifically in the merozoite stage
(color of individual gene expression profiles based on the Mc52
expression). Three candidate genes for use in cloning merozoite
specific promoters are highlighted (blue). (B) Transgenic GRA1, MSF
and SRS22B strains were assessed for expression of DHFR-Ty at the
tachyzoite (α-Ty + Alexa Fluor 488, yellow and α-SAG1-Alexa Fluor 594,
red) and bradyzoite (α-Ty + Alexa Fluor 488, yellow and α-BAG5 + Alexa
Fluor 594, red) stages by IFA. Strong nuclear expression of DHFR-Ty was
observed for the GRA1 strain and lacked expression for MSF and
SRS22B strains at both stages, which tracks with the microarray
expression data (Figure 4A and Figure 6A). (C) The MSF strain was
assessed for enteric stage expression of DHFR-Ty in the felid intestine
(α-Ty + FITC, yellow and α-RH-parasite + TRITC, red). Non-transgenic
TgNmBr1 parasite was used as a negative control. Expression of
DHFR-Ty was observed for the MSF strain in the enteric stage,
confirming stage specific control of expression by the promoter.
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Lastly, in order to test the developmental regulation of ex-
pression during enteric development, mature bradyzoite
cysts of parasites harboring pMSF were generated in
chronically infected mice and fed to a cat for the produc-
tion of oocysts. At the first indication of shed oocysts, the
intestine was harvested and processed for IHC. As a con-
trol we used an IHC prepared section of the intestine in-
fected with the original TgNmBr1 strain that was used to
harvest merozoite mRNA (Figure 1B). In contrast to tissue
culture, where the pMSF driving expression of DHFR-Ty
was not detected, parasites in the gut labeled brightly with
α-Ty antibody (Figure 6C). No Ty labeling was seen in the
TgNmBr1 sample (Figure 6C). The labeling pattern seen
for the MSF strain in Figure 6 B & C matches what was
predicted from the expression data (Figure 6A) and shows
that upstream regions are sufficient to control expression
of a merozoite gene. Much like developmental regulation
in the intermediate stages, cis elements and specific fac-
tors that bind them to control gene expression are active
in the enteric stages.
Discussion
Here we describe the global gene expression of the mer-
ozoite stage of Toxoplasma gondii and analyzed this
stage in context of the life cycle in combination with
previously published array data from other life cycle
stages [27]. We confirm that the expression patterns ob-
served for the merozoite samples matched data on pro-
tein expression for enteric stage parasites [20]. We also
substantially extend these prior studies by showing that
many parasite specific gene families such as GRAs, ROPs
and MICs were downregulated at the merozoite stage.
Functions for many members of these families have been
described for the intermediate stages of the parasite, and
the regulation at the merozoite stage suggests that these
genes are not needed during intraepithelial development
in the definitive host. Interesting, genes known to be crit-
ical for moving junction formation and thus parasite in-
vasion during the intermediate stages are not expressed
in the merozoite. Although not much is known about how
merozoites invade, the shared morphological character-
istics of tachyzoites and merozoites suggests an active
invasion process, which based on the expression data is
not reliant on known RON/AMA interactions. Speciation
of apicomplexan parasites may have occurred via evolu-
tionary divergence of definitive hosts [44,45]. Many mem-
bers of the parasite-specific gene families are the result
of gene duplication and expansion events, and those
few members that are upregulated at the merozoite stage,
the first stage the parasite differentiates into within the
definitive host, may represent the ancestral copies from
which the expanded intermediate stage expressed genes
arose.
Figure 7 Characterization of transgenic strains. (A) Schematic of
the DHFT-Ty expression cassette in the three pDEST-(*)p-DHFR-Ty
plasmids and the locations of primers used in (B). (B) PCR analysis of
transgenic Me49-Fudr clones to detect plasmid integration: G1 and
G2 – GRA1p specific primers, ladder - 1 kb ladder (New England
Biolabs), n (no template control), M (Me49 template), M + (Me49
transgenic clone template). (C) Growth of transgenic Me49-Fudr
clones with or without the drug pyrimethamine. All three transgenic
clones grew, creating plaques, in normal D10 media without drug
(top). Only the Me49-GRA1p-DHFR-Ty clone grew in D10+ pyrimethamine
(bottom, *indicates disturbance of the monolayer due to mechanical
means, not parasite growth).
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gene expression continuum of the T. gondii life cycle,
clustering between tachyzoite/bradyzoite and oocyst
samples as shown by PCA. It will be of interest to isolate
other enteric forms of Toxoplasma, such as the micro-
and macrogamete for global gene expression studies to
determine if the missing forms will follow this progres-
sion, thus being placed between the merozoite and oo-
cysts clusters. Additionally, a large number of genes
were regulated when the parasites enter coccidian devel-
opment. Many of these genes related to cell growth/
maintenance (Translation and Transcription GO cat-
egories) and metabolic processes (Glycolysis and TCA
Cycle GO categories) were upregulated at the merozoite
stage. Different than the intermediate stages, the mero-
zoite divides by processes similar to schizogony termed
endopolygeny, where multiple daughters are generated
before the plasma membrane resolves the individual par-
asites [46]. It is possible that the merozoite specific up-
regulation of cell growth and metabolism related genes
is a consequence or even a requirement for the endopo-
lygeny form of division. On the other hand, the elevated
expression of growth and metabolism related genes is
reminiscent of the Warburg effect, where, for example,
cancer cells within hypoxic tumor microenvironments
increase expression of metabolism related genes, such as
glycolysis [47]. The merozoite preferably grows in the
microaerobic environment of the small intestine and it
may be the hypoxic nature of the small intestine [48]
that partially explains the unique expression pattern of
growth and metabolic related genes in the merozoite.
We also demonstrate that promoter control of gene
expression is conserved at the merozoite stage. Quite a
number of conserved motifs were found in co-regulated
genes, whether when ordering genes by the maximum
or minimum of expression. Identifying conserved over-
represented motifs by ordering genes in this manner
may indicate regulatory control for a particular motif.
For example, the large number of motifs overrepresented
throughout the life cycle when genes were ordered by
the minimum of expression indicates that these motifs
correspond to points in the life cycle when expression is
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mechanisms. Indeed, recently the AP2 transcription fac-
tor, AP2IX-9, was shown to operate as a repressor by
inhibiting bradyzoite-specific gene expression [49], a role
many of the 67 annotated AP2 genes, or other cis elem-
ent binding proteins, in Toxoplasma may share. In
addition to identifying conserved motifs associated with
gene expression patterns, we confirm that a merozoite
specific promoter is sufficient to control the stage spe-
cific expression of a reporter gene.
The microarray data of Toxoplasma merozoites pro-
vide a global gene expression dataset for this stage. Not
only will this information be valuable in understanding
the life cycle of Toxoplasma, it can be used to develop
reagents and tools to further characterize the develop-
mental biology of the sexual stages of coccidian para-
sites. For example, the transgenic parasites developed in
this study, which express drug selectable markers only at
the merozoite stage, will be used in forward selection
strategies to screen for tissue culture conditions that are
favorable to merozoite growth. As the merozoite is the
first stage the parasite differentiates into within the gut
of the definitive host, it is the first hurdle to better
understand the sexual stages of the parasite. If we can
determine the correct conditions that coax the parasite
into the merozoite stage in vitro, those conditions may
be sufficient to allow the parasite to complete sexual
development.
Epithelial gut stages are a common life cycle feature of
apicomplexan parasites, and most often the sexual stages
develop in the gut, whether the host be vertebrate or in-
vertebrate. This shared tropism is the result of the pas-
sive route of ingestion with which the parasite can gain
access to and exit from the host. The triggers and spe-
cific processes that control parasite differentiation within
gut environments are relatively unknown for apicom-
plexan parasites. In large part, this is because there are
no tissue culture systems for gut stages. For example, it
is necessary to use mosquitoes to perform crosses in
Plasmodium [50] and to use chickens to grow Eimeria
tenella [51]. It is not for lack of trying that efforts
haven’t been successful in the past, but with the advent
of -omic technologies these efforts can be re-explored.
Using genomic based technologies the unique molecular
characteristics of gut stages can be acquired and assessed
for possible drivers of differentiation. This strategy has re-
cently led to a major advance in understanding the tsetse
fly specific developmental stages of Trypanosome brucei.
Analysis of transcriptional data allowed researchers to
show for the first time that the expression of just one
RNA-binding protein in procyclics induced them in vitro
into long and short form epimastigotes and eventually in-
fectious metacyclics [52]. This approach has the potential
to work in other systems, such as Toxoplasma that hasmany tools already developed for study, and may reveal
unique and/or shared aspects of apicomplexan gut stage
development.Conclusions
Merozoites are the first developmental stage in the coc-
cidian cycle that takes place within the gut of the defini-
tive host. The data presented here describe the global
gene expression profile of the merozoite stage and the
creation of transgenic parasite strains that show stage-
specific expression of reporter genes in the cat intestine.
These data and reagents will be useful in unlocking how
the parasite senses and responds to the felid gut envir-
onment to initiate enteric development.Methods
Ethics statement
Laboratory mice were used for maintaining chronic in-
fections of the parasite T. gondii. Mice were housed ac-
cording to instructions in the “Guide to Care and Use of
Laboratory Animals” under supervision of a fully trained,
veterinary staff in the Washington University Animal
Care Facility. Protocols were approved by the Institu-
tional Care Committee and are covered by animal wel-
fare assurance number A-3381-01.
Members of the cat family are the only known host for
the sexual stages of T. gondii. Protocols were conducted in
the laboratory of Dr. J. P. Dubey at the USDA in Beltsville
MD. Dr. Dubey’s laboratory is approved for these proce-
dures by USDA, ARS, Beltsville Agricultural Research
Center Animal Care Committee (BAACUC) and are cov-
ered by animal welfare assurance number A4400-01.Parasite lines and tissue culture
The type II TgNmBr1 strain was provided by J.P. Dubey
[25]. The type II Me49-Fudr strain was used to make
transgenic parasites [53]. For tissue culture, parasites
were grown in human foreskin fibroblasts (HFFs) in
Dulbecco’s Modified Eagle’s Medium (DMEM) (Gibco)
supplemented with 10% fetal bovine serum (FBS)
(HyClone) at 37°C with 5% CO2. For the plaque assays,
parasites were seeded to confluent HFF monlayers at ei-
ther 100 or 2000 per well and allowed to grow for 9 days
(+/−pyrimethamine (Sigma), 10 μM), at which time the
monolayers were washed with PBS, fixed with 100%
ethanol and stained with Crystal Violet (.05%).
The TgNmBr1 parasite was grown in tissue culture as
tachyzoites for mRNA isolation. Two day infected HFF
monolayers were scrapped, needle passed, and parasites
filtered through a 3 μm polycarbinate membrane (GE).
Filtered parasites were spun at 1,410 rpm and parasite
pellets were frozen at −80°C until processed for mRNA.
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To produce intraepithelial intestinal sexual stage para-
sites, the TgNmBr1 strain was intraperitoneally (i.p.)
injected into mice that were allowed to develop chronic
infections characterized by tissue cysts containing brady-
zoites. After 30 days, brains from the infected mice were
harvested and fed to three separate cats (c48, c50, and
c52). Production of oocysts was monitored, and once
oocysts were detected (5–6 days post feeding), the small
intestine was harvested and placed in 1X PBS with anti-
biotics and kept at 4°C. To harvest sexual stage para-
sites, intestines were flayed open, lightly scrapped to
remove the mucus and first layer of intestinal cells,
and the scrapped material was suspended in PBS. Sam-
ples were passed through progressively smaller needles
(16G – 23G) to break host cells and debris, and centri-
fuged in an Eppendorf 5810R centrifuge at 400 rpm to
remove large material. The supernatant was filtered
through 3 μm membranes, centrifuged at 1,410 rpm to
pellet parasites, and parasite pellets were frozen at −80°C
until processed for RNA. A portion of each sample was
resuspended in PBS and observed for purity under the
microscope. The harvesting process resulted in remov-
ing the majority of host cells and debris, leaving crescent
shaped felid intestinal derived parasites.
To test enteric stage expression of the MSF promoter,
the transgenic Me49-Fudr-MSFp-DHFR-Ty parasite
was i.p. injected into CD-1 mice to generate in vivo
bradyzoite cysts. After 30 days, mice were sacrificed
and cysts were isolated from brain samples and kept
on ice until fed to a cat. The cat was monitored for oo-
cyst shedding, and once oocysts were observed, the intes-
tine was harvested, fixed in 10% formalin, and processed
for IHC.
RNA isolation and microarray hybridization
The Qiagen RNeasy kit (Qiagen) was used to harvest RNA
as described previously [28]. Briefly, frozen parasite pellets
were resuspended in RLT buffer with β-mercaptoethanol
and processed on the RNeasy column. Samples were
treated with DNase and resuspended in deionized water
and frozen at −80°C. RNA quality was determined on
an Agilent Bioanalyzer (Agilent Technologies). The RNA
quality was good, showing lack of degradation and little
host contamination. Two samples for the c52 RNA,
one each for the c48 and c50 RNA, and two for tachy-
zoite TgNmBr1 RNA were labeled using the Ambion
MessageAmp Premier RNA Amplification Kit (Life
Technologies) using 500 ng total RNA. Using standard
hybridization protocols, 5.5 μg of labeled cRNA was hy-
bridized to the Affymetrix Toxoplasma GeneChip [26]
and imaged with an Affymetrix GeneChip Scanner (Affy-
metrix). The microarray CEL files created for this study
have been deposited at NCBI GEO submission GSE51780.Microarray data processing and analysis
To analyze the merozoite gene expression in context of
the life cycle we obtained a previously published set of
arrays from NCBI GEO GSE32427 [27], comprising the
following sample types; day 0, 4, 10 oocyst (OD0, OD4,
OD10), day 2 tachyzoite (TD2), and day 4, 8, 21 bradyzoite
(BD4, BD8, BD21). Arrays from GSE32427 and those hy-
bridized for this study (TNm, Mc48, Mc50, Mc52),
GSE51780, were combined and analyzed as a set. Micro-
array data were loaded into R using the “affy” library and
processed using Robust Multi-array Average (RMA) and
quantile normalization [54]. RMA normalization con-
verged the distributions and medians across all samples.
RMA normalized data were used in subsequent ana-
lyses. The log2 RMA normalized intensity values can be
acquired from NCBI GEO submission GSE51780. Anno-
tations and Gene Ontology (GO) assignments were ob-
tained from ToxoDB.org [55].
R normalized values were imported into GeneSpring
(Agilent Technologies). Duplicate samples were grouped
by type and average values were calculated. To identify
those 8,131 Toxoplasma probesets, or genes, represented
on the microarray with significant gene expression dif-
ferences across sample types we used the following cri-
teria: 1. genes with raw expression values of 30 or lower in
all samples were flagged as not expressed and removed
from analysis. This removed 1571 genes. 2. An analysis of
variance (ANOVA) test was run on the remaining 6560
genes using a p-value cutoff of .05 and multiple testing
correction: Benjamini and Hochberg False Discovery Rate.
There were 43 genes that had insufficient data. This pro-
cedure identified 5969 genes significantly different in at
least one sample across the experiment, of which 5% (298)
may have been called by chance.
Heatmaps were generated using gene tree clustering
with the standard correlation similarity measure.
PCA: Principle component analysis (PCA) was carried
out on the 5,969 gene set by sample type, or condition,
to determine the strongest expression themes in the
data. This method calculates the standard correlation be-
tween each condition vector and each eigenvector, or
principal component vector. PCA identified three princi-
pal components (PCA1: 43% variance, PCA2: 32.2% vari-
ance, PCA3: 10% variance), together these comprise 85%
of the variance across sample types.
Spline curves: To accurately describe expression pro-
files across the life cycle for the 5,969 significantly differ-
entially expressed genes we used the spline function in
R. The TNm, BD4, BD21, Mc48, and Mc50 samples were
not included in spline analysis as they are correlative to ei-
ther the TD2, BD8, Mc52 samples. The excluded samples
essentially represent replicate sample types for many genes
that would hinder the correct determination of maximum
and minimum spline values, confounding the ordering or
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curve was generated for each of the non-redundant 5969
genes using a “n” number of points 20*length (dataset)
and the “natural” spline method. The global maximum
and minimum, or extrema, spline values for each gene
were determined, which correspond to points of max-
imum and minimum expression across the life cycle for a
particular gene. The spline function was also used to de-
termine the extrema of the first derivative, f ’(x), using
“splinefun” and “deriv = 1”. The extrema of the first de-
rivative are the inflection points along the spline curve
that correspond to the maximum rate of synthesis or deg-
radation for a particular gene. The differences between
maximum, or minimum, expression and the respective
rate values were calculated to determine the time to ma-
ximum or minimum expression.
FIRE: To identify putative cis elements in the 5’ re-
gions of co-regulated genes across the life cycle we used
the Finding Informative Regulatory Elements (FIRE) pro-
gram [41]. Sequence 2,000-0 bp 5′ of each gene was ob-
tained from ToxoDB.org [55] and combined with the
continuous dataset of ordered genes according to the
maximum or minimum of expression. A minimum cut-
off z-score of 8.5 was used and motifs were sorted by
phase of expression. No significant motifs were found
for 100 permutations of randomly ordered genes. Also,
no significant motifs were found for correctly ordered
maximum of expression genes and only one significant
motif was found for minimum of expression genes when
compared to sequence 4,000-2,000 bp 5′ of each gene,
and no significant motifs were found when correctly or-
dered genes were compared to sequence 6,000-4,000 bp
5′ of each gene.
KEGG: Normalized ratio expression values were used to
map genes and expression into the Kyoto Encyclopedia of
Genes and Genomes (KEGG) [56]. The Toxoplasma
gondii genome is represented at KEGG, entry T01093,
and life cycle regulated genes with KEGG assignments
were mapped onto the PathwayMap using the KegArray
program, pathways 2 fold downregulated (blue), non-
regulated (yellow), and 2 fold upregulated (red). Images
for the Metabolic Pathways map (tgo01100) were obtained
for each sample and a GIF file was created using the con-
vert program.
Immunofluorescence, immunohistochemistry and microscopy
For IFA: Extracellular merozoite parasites were adhered
to poly-L-lysine treated coverslips. Intracellular parasites
were imaged on coverslips with infected HFF monolayers.
All coverslips were fixed with 4% formaldehyde with .01%
TritonX-100 in 1X PBS. Coverslips were blocked with 5%
Fetal-bovine/Normal goat serum (FBS/NGS) in PBS. Cov-
erslips were mounted in Prolong Gold containing DAPI
(Life Technologies).For IHC: Felid intestines were fixed in 10% formalin
and stored in 70% EtOH. Samples were mounted in pa-
raffin tissue blocks and thin sectioned.
For IFA and IHC: Antibodies were suspended in 1X
PBS with 1% FBS. Primary antibodies used were all diluted
1:1,000 and include; mouse α-Me49, rabbit α-RH, mouse
α-Ty, conjugated α-SAG1-594, and rabbit α-BAG5 (BAG5
is an alternate name for BAG1). Alexa Fluor 488 α-mouse
or Alexa Fluor 595 α-rabbit (Life Technologies) were used
for the secondary at 1:1000. Images were obtained on a
Zeiss Axioskop 2 MOT Plus microscope using a AxioCam
MRm camera (Carl Zeiss, Inc.).
Plasmid construction and creation of transgenic parasites
To construct the merozoite promoter expression plas-
mids we used the pDEST-GRA1p as a template. The
pDEST-GRA1p plasmid has a Destination Gateway clon-
ing site flanked by an upstream TgGRA1 promoter
(GRA1p) and a downstream TgDHFR 3′ UTR, and con-
tains a bleomycin cassette for selection in Toxoplasma.
The GRA1p (611 bp) was excised from pDEST-GRA1p
using the Hind-III and Bgl-II restriction enzymes and re-
placed with either the MSF (998 bp upstream of the start
codon) or the SRS22B (672 bp upstream) promoters that
were amplified from type II Me49 lysate using the iProof
polymerase (Bio-Rad Laboratories) with standard PCR
amplification techniques, resulting in pDEST-MSFp and
pDEST-SRS22Bp plasmids. Primers used to amplify the
merozoite promoters: Megap Hind-III for (1) (5′-CTAG
TAAGCTTTCTCCCCTGGGAAAAGACAGG-3′), Megap
Bgl-II rev (5′-CTAGTAGATCTGCCGTTTTGGTGCGT
CCAAG-3′), SRS22Bp Hind-III for (1) (5′-CTAGTA
AGCTTCTGTGCGTCCTCCACCTTC-3′), SRS22Bp Bgl-
II rev (5′-CTAGTAGATCTCTTGAATTAACTGAGAC
CAGGGCCAC-3′). To create a Gateway cloning fragment
for the pDEST plasmids, the pyrimethamine resistant
DHFR gene was cloned into the pDONR221 plasmid with
a C-terminal Ty tag using the standard BP reaction proto-
col, resulting in pDONR-DHFR-Ty. Primers used to clone
pDONR-DHFR-Ty: DHFR-Ty CDS attB1 for (5′-GGGGA
CAAGTTTGTACAAAAAAGCAGGCTTCATGCAGAA
ACCGGTGTGTCTGG-3′), DHFR-Ty CDS attB2 rev (5′-
GGGGACCACTTTGTACAAGAAAGCTGGGTCATC
GAGCGGGTCCTGGTTCGTGTGGACCTCGACAGCC
ATCTCCATCTGGA -3′). The pDONR-DHFR-Ty plas-
mid was then cloned into the three pDEST plasmids using
the LR reaction to create, pDEST-GRA1p-DHFR-Ty,
pDEST-MSFp-DHFR-Ty, and pDEST-SRS22Bp-DHFR-Ty.
The three plasmids were individually electroporated into
Me49-Fudr, parasites were selected with phloemycin using
standard protocols [57], cloned, and screened for plasmid
integration using specific primers (See Figure 6A). Primers
used to screen clones (for (1), see above): GRA1p for (G1)
(5′- AAACCCTCGAAGGCTGCTAGTACT 3′), GRA1p
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CAGCAAG-3′), DHFR-Ty in 5′ of CDS rev (2) (5′- CC
CGTCTTTGCAAATTTCCTGG-3′), DHFR 3′ UTR rev
(3) (5′- CCGCGGTGTCACTGTAGCC -3′). This re-
sulted in three transgenic strains; Me49-GRA1p-DHFR-
Ty (GRA1 strain), Me49-MSFp-DHFR-Ty (MSF strain)
and Me49-SRS22Bp-DHFR-Ty (SRS22B strain).
Availability of supporting data
Microarray CEL files and log2 normalized intensity values
are available at NCBI GEO, http://www.ncbi.nlm.nih.gov/
geo/, under Accession number GSE51780.
Additional files
Additional file 1: KEGG maps. Description: KEGG maps for life cycle
regulated genes were created for each of the microarray samples and
combined together into a GIF file. Expression of genes that mapped to
a particular metabolic pathway are indicated by colored lines; 2 fold
downregulated (blue), non-regulated (yellow), and 2 fold upregulated
(red), gray lines are pathways without a mapped gene.
Additional file 2: Raw Expression Data. Description: Excel file with
raw expression values for all genes across all samples used in this study.
Genes are grouped by expression type, color coding denoted at the top
of the file.
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